Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
Physiol Int ; 106(4): 323-334, 2019 Dec 01.
Article in English | MEDLINE | ID: mdl-31619044

ABSTRACT

Betulin, a pentacyclic triterpene, possesses antioxidant, anti-inflammatory and hepatoprotective properties. The aim of this study was to evaluate the impact of liver mitochondria in hepatoprotection of betulin using a rat model of alcoholic steatohepatitis induced by ethanol administration (4 g/kg, intragastric) for 8 weeks. The treatment with betulin (50 and 100 mg/kg b.w., intragastric) during this period attenuated the histological signs of steatohepatitis and lowered the serum and liver triglyceride contents, as well as the serum activities of aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase. Betulin (100 mg/kg) decreased the liver/body weight ratio and inhibited the increase in the serum levels of TNFα, IL-1ß, TGFß, and hyaluronic acid, demonstrating hepatoprotective, anti-inflammatory, and antifibrotic potential. Betulin also inhibited the formation of superoxide anions in mitochondria and the end-products of lipid peroxidation in liver tissue, the amount of which was significantly increased in ethanol-treated rats. The disturbances in mitochondrial respiration, uncoupling of oxidative phosphorylation and decreasing of mitochondrial complex I, II, and IV activities in rats with steatohepatitis, were reverted by betulin administration. The increased susceptibility of mitochondria to Ca2+-induced permeability transition pore formation in the hepatitis group was improved in rats treated with betulin. In conclusion, betulin, having antioxidant properties, exerts a beneficial effect in the rat model of alcoholic steatohepatitis via prevention of liver mitochondria dysfunction, which may be attributed to the inhibition of mitochondrial permeability transition.


Subject(s)
Fatty Liver, Alcoholic/drug therapy , Fatty Liver/prevention & control , Liver Diseases/prevention & control , Liver/drug effects , Mitochondria/drug effects , Mitochondrial Diseases/prevention & control , Triterpenes/pharmacology , Alanine Transaminase/metabolism , Animals , Antioxidants/metabolism , Aspartate Aminotransferases/metabolism , Fatty Liver/metabolism , Fatty Liver, Alcoholic/metabolism , Lipid Peroxidation/drug effects , Liver/metabolism , Liver Diseases/metabolism , Male , Mitochondria/metabolism , Mitochondria, Liver/drug effects , Mitochondria, Liver/metabolism , Mitochondrial Diseases/metabolism , Oxidative Stress/drug effects , Rats , Rats, Wistar , Triglycerides/metabolism
2.
Phytother Res ; 26(11): 1626-31, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22359349

ABSTRACT

The aim of study was to evaluate the hepatoprotective effect of borage oil containing predominantly gamma-linolenic acid in rats with alcoholic steatohepatitis. Liver of ethanol-treated animals was characterized by fatty and hydropic dystrophies. Liver triglyceride contents and activitiies of serum marker enzymes were significantly increased. Ethanol increased nicotinamide adenine dinucleotide phosphate hydrogen (NADPH)-induced chemiluminescence and the contents of liver thiobarbituric acid reactive substances (TBARS). The reduced glutathione content in the liver was decreased. Ethanol enhanced liver microsomal cytochrome P-450 (CYP450) content, aniline p-hydroxylase and amydopyrine-N-demethylase activities. The treatment with borage oil improved the liver morphology, decreased triglyceride contents and normalized serum marker enzyme activities. Borage oil developed an antioxidant effect in ethanol-treated rats. The treatment with this compound decreased NADPH-induced chemiluminescence and the content of lipid peroxidation products. Borage oil normalized CYP450 content compared with the ethanol-treated group. CYPI450 2E1 isoform is a main source of free oxygen radicals in the liver of ethanol-treated rats and we propose that the antioxidant effect of borage oil is realized via the normalization of CYP450 content and activities of CYP450-related microsomal oxidases, as borage oil can improve the lipid surrounding of CYP450. In our opinion, the hepatoprotection by borage oil in alcoholic steatosis is connected with its antioxidant properties.


Subject(s)
Fatty Liver, Alcoholic/drug therapy , Liver/drug effects , Plant Oils/pharmacology , gamma-Linolenic Acid/pharmacology , Aminopyrine N-Demethylase/metabolism , Aniline Hydroxylase/metabolism , Animals , Antioxidants/pharmacology , Cytochrome P-450 Enzyme System/metabolism , Ethanol , Lipid Peroxidation/drug effects , Liver/enzymology , Male , Microsomes, Liver/enzymology , NADP/analysis , Rats , Rats, Wistar , Thiobarbituric Acid Reactive Substances/analysis , Triglycerides/analysis
3.
Eur J Clin Invest ; 38(5): 317-25, 2008 May.
Article in English | MEDLINE | ID: mdl-18380797

ABSTRACT

BACKGROUND: Stimulation of nitric oxide (NO) synthesis similar to the application of NO donors could be of benefit in liver fibrosis. Many authors believe that activation of NO synthesis by pharmacological agents is promising in the treatment of liver fibrosis. However, there is considerable controversy in understanding the role of NO in fibrogenesis and fibrolysis. The aims of our study were to evaluate the effects of L-arginine, as an NO metabolic precursor, and those of NO synthase (NOS) inhibitors, L-nitroarginine methyl ester (L-NAME) and aminoguanidine (AG) in rats with thioacetamide (TAA)-induced liver fibrosis reversal. MATERIALS AND METHODS: Male Wistar rats, 230-240 g, received TAA (200 mg kg(-1), intraperitoneally) twice a week for 3 months. Liver resolution was simulated by withdrawal of TAA administration. Thereafter the animals were subdivided into five groups and treated by intragastric intubation with: L-arginine (100 and 300 mg kg(-1)); L-NAME as an inhibitor of both constitutively expressed NOS (eNOS) and inducible NOS (iNOS) (20 mg kg(-1)), AG as a specific inhibitor of iNOS (100 mg kg(-1)) or placebo. The severity of liver fibrosis was assessed by morphometric evaluation of liver slides stained with Azan-Mallory, hydroxyproline (Hyp) determination and mRNA steady state levels of collagen I, transforming growth factor (TGF)-beta1, metalloproteinases (MMP)-13, -14, tissue inhibitor of MMP (TIMP)-1 and plasminogen activator inhibitor (PAI)-1 were quantified by real time PCR. The activities of serum marker enzyme, alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase, were measured. RESULTS: TAA treatment during 3 months induced micronodular liver fibrosis with a pronounced deposition of collagen fibres. L-Arginine did not affect this deposition nor did it affect both relative and total liver hydroxyproline content. Both NOS inhibitors significantly increased the square of the liver connective tissue stained by Azan-Mallory and the above parameters characterizing liver hydroxyproline content. Both NOS inhibitors up-regulated procollagen alpha1 (I), MMP-13, TIMP-1 and PAI-1 mRNA expression. The AG effects were more pronounced. than those of L-NAME. AG treatment also increased mRNA expression of TGF-beta1 and PAI-1. CONCLUSIONS: Both NOS inhibitors developed a clear pro-fibrotic effect in the liver. Aminoguanidine was more fibrotic than L-NAME. Our data suggest a significant anti-fibrotic role for iNOS rather than for eNOS. L-Arginine did not show any anti-fibrotic properties in the TAA-model used.


Subject(s)
Enzyme Inhibitors/pharmacology , Liver Cirrhosis/enzymology , Liver Regeneration/drug effects , Liver/enzymology , Nitric Oxide Synthase Type II/antagonists & inhibitors , Thioacetamide/pharmacology , Animals , Arginine/pharmacology , Disease Models, Animal , Liver Cirrhosis/chemically induced , Liver Cirrhosis/pathology , Male , Nitric Oxide Synthase Type II/metabolism , Rats , Rats, Wistar
4.
Adv Med Sci ; 51: 54-9, 2006.
Article in English | MEDLINE | ID: mdl-17357278

ABSTRACT

PURPOSE: The aim of this study was to evaluate the role of an antioxidant factor in the hepatoprotective effect of ursodeoxycholic acid (UDCA) in rat alcoholic steatohepatitis. MATERIAL AND METHODS: The effects of UDCA (40 mg/kg, i.g., 30 days) were studied using rats fed on a high-fat diet (52% calories as fat) and administered with ethanol via intragastric intubation (4 g/kg daily, 30 days). RESULTS: The livers of ethanol-treated animals were characterized by fatty dystrophy. The relative liver weight and the square of the sudanophylic area as well as the liver triglyceride content and the activity of the serum marker enzymes, aspartate aminotransferase and gamma-glutamyltransferase, were significantly increased. Elevated superoxide dismutase activity as well as increased contents of lipid peroxidation products (hydroxyalkenals, malone dialdehyde, etc.) and lucigenin-enhanced microsomal chemiluminescence were observed in the liver of ethanol-treated rats and the liver reduced glutathione content was decreased. An increase in monoenoic fatty acids, a decrease of the n-6 acid family and an enhancement of microsomal membrane viscosity were found in the liver of these animals. An elevation of the total cytochrome P-450 content and the activity of amidopyrine-N-demethylase were shown in liver microsomes of the ethanol-treated group. The UDCA treatment improved the liver morphology, decreased serum marker enzyme activities, liver triglyceride content and normalized all the indices of oxidative stress. UDCA lowered the viscosity of the microsomal membrane, as assessed by both the fluorescence probe techniques and the saturated/unsaturated fatty acid ratio. The microsomal cytochrome P-450 content and amidopyrine-N-demethylase activity were normalized in UDCA-treated rats. CONCLUSIONS: We can conclude that the hepatoprotective effect of UDCA stipulated by its antioxidant properties is indeed the factor enabling UDCA to control metabolic processes by changing the properties of liver membranes and membranous proteins.


Subject(s)
Antioxidants/metabolism , Fatty Liver, Alcoholic/prevention & control , Liver/drug effects , Ursodeoxycholic Acid/pharmacology , Animals , Aspartate Aminotransferases/metabolism , Cholagogues and Choleretics/pharmacology , Dietary Fats/administration & dosage , Dietary Fats/toxicity , Disease Models, Animal , Ethanol/administration & dosage , Ethanol/toxicity , Fatty Acids/metabolism , Fatty Liver, Alcoholic/etiology , Fatty Liver, Alcoholic/metabolism , Glutathione/metabolism , Lipid Peroxidation/drug effects , Liver/metabolism , Liver/pathology , Male , Microsomes, Liver/drug effects , Microsomes, Liver/metabolism , Microsomes, Liver/pathology , Rats , Rats, Wistar , Superoxide Dismutase/metabolism , Triglycerides/metabolism , gamma-Glutamyltransferase/metabolism
5.
Pol J Pharmacol ; 56(5): 599-604, 2004.
Article in English | MEDLINE | ID: mdl-15591649

ABSTRACT

The present study was designed to examine the effects of the donor of nitric oxide (NO), NaNO(2) and the inhibitor of NO synthase, N(omega)-nitro-L-arginine (L-NNA), on the development of dimethylnitrosamine (DMNA)-induced chronic hepatitis in rats. L-NNA decreased rat survival and enhanced the severity of hepatic encephalopathy in the DMNA-treated animals. The aggravation of the morphological signs of hepatitis, the activation of serum alanine aminotransferase and cytosolic superoxide dismutase activities and the increase in the liver malondialdehyde content were observed in this group. The treatment with NaNO(2) improved liver morphology, decreased serum marker enzyme activities, lowered the activities of alpha-D-mannosidase and N-acetyl-beta-D-glucosaminidase compared to the DMNA-treated group. The results of the morphological and biochemical studies suggest that L-NNA increased DMNA-induced liver damage, whereas NaNO(2) partially prevented the development of chronic hepatitis. It is proposed that the opposite effects of L-NNA and NaNO(2) are partially explained by a modulation of the free radical-dependent processes in the liver.


Subject(s)
Chemical and Drug Induced Liver Injury/metabolism , Dimethylnitrosamine/toxicity , Hepatitis, Chronic/metabolism , Nitric Oxide Donors/pharmacology , Nitric Oxide Synthase/antagonists & inhibitors , Nitroarginine/pharmacology , Animals , Chemical and Drug Induced Liver Injury/drug therapy , Hepatitis, Chronic/drug therapy , Liver/drug effects , Liver/metabolism , Male , Nitric Oxide Donors/therapeutic use , Nitric Oxide Synthase/metabolism , Nitroarginine/toxicity , Rats , Rats, Wistar
6.
Ukr Biokhim Zh (1999) ; 74(1): 88-92, 2002.
Article in English | MEDLINE | ID: mdl-12199106

ABSTRACT

We studied effects of ursodeoxycholic acid (UDCA) (10 and 100 mg/kg b.w.) on the free radical generation, lipid peroxidation and the antioxidant defense system in the liver of rats with oxidative stress caused by gamma-irradiation. Both doses of UDCA normalized the liver parameters enhanced by gamma-irradiation: the content of superoxide anion and carbonyl-containing products of lipid peroxidation (alkanals, alkenals, alkadienals and ketones), the superoxide dismutase activity and the chemiluminescence enhanced by luminol. Only the highest dose of UDCA (100 mg/kg b.w.) decreased the chemiluminescence enhanced by lucigenin in liver microsomes and the hydroxyalkenals content in the liver. UDCA prevented reduced glutathione depletion caused by gamma-irradiation, whereas glutathione-related enzyme activities did not change under the influence of both the UDCA doses as well as gamma-irradiation. Thus, the data obtained suggest that UDCA is a metabolite having the sufficiently effective antioxidant properties.


Subject(s)
Antioxidants/pharmacology , Liver/radiation effects , Oxidative Stress , Ursodeoxycholic Acid/pharmacology , Animals , Dose-Response Relationship, Drug , Gamma Rays , Lipid Peroxidation , Liver/drug effects , Liver/metabolism , Luminescent Measurements , Male , Rats
7.
Alcohol ; 25(2): 99-105, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11747979

ABSTRACT

The aim of the present study was to evaluate the effect of ursodeoxycholic acid (UDCA) on prostaglandin and fatty acid metabolism and the possible relation of these substances to the development of alcoholic fatty liver in rats. The effects of UDCA (40 mg/kg/day, 30 days) were studied in rats pair-fed a high-fat diet (52% of calories as fat) with daily ethanol (4 g/kg/day, 30 days) intragastric intubation. The livers of ethanol-treated animals were characterized by fatty dystrophy. Liver triglyceride and cholesterol ester contents and the activities of serum marker enzymes, alanine aminotransferase and gamma-glutamyltransferase, were significantly increased. Ethanol enhanced phosphoinositol and sphingomyelin content in liver microsomes and lowered prostaglandin E(2) (PGE(2)) concentration in the liver. An increase in the percentage of monoenoic fatty acids and a decrease in the n-6 acid family in liver phospholipids, linoleoyl-CoA desaturase, and PGE(2) synthase activities in liver microsomes were observed in ethanol-treated rats. Treatment with UDCA improved liver morphologic characteristics, decreased triglyceride and cholesterol ester contents, increased the PGE(2) level, and normalized linoleoyl-CoA desaturase and PGE(2) synthase activities, as well as phospholipid and fatty acid patterns in the liver. The activities of the serum marker enzymes were decreased in the ethanol- and UDCA-treated group. Ursodeoxycholic acid lowered the viscosity of the microsomal membrane, as assessed by both fluorescence probe techniques and the saturated/unsaturated fatty acid ratio. We propose that the hepatoprotective effect of UDCA in alcoholic fatty liver is related to the stabilization of microsomal membranes, the prevention of a decrease in essential fatty acids and PGE(2) in the liver, and, probably, an improvement in biochemical processes controlled by PGE(2).


Subject(s)
Cholagogues and Choleretics/pharmacology , Dinoprostone/metabolism , Fatty Liver, Alcoholic/metabolism , Intracellular Membranes/drug effects , Microsomes, Liver/drug effects , Ursodeoxycholic Acid/pharmacology , Animals , Cell Polarity/drug effects , Central Nervous System Depressants/pharmacology , Cholagogues and Choleretics/therapeutic use , Ethanol/pharmacology , Fatty Acids/metabolism , Fatty Liver, Alcoholic/prevention & control , Intracellular Membranes/chemistry , Lipid Metabolism , Male , Microsomes, Liver/chemistry , Rats , Rats, Wistar , Ursodeoxycholic Acid/therapeutic use , Viscosity/drug effects
8.
Climacteric ; 4(1): 49-57, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11379378

ABSTRACT

OBJECTIVE: The aim of this study was to investigate the antiatherogenic effects of 17 beta-estradiol and 17 alpha-estradiol and its derivative J811 (estra-1,3,5(10),8-tetraene-3, 17 alpha-diol), having a non-feminizing effect and high antioxidant potential, in male rabbits. EXPERIMENTAL DESIGN: Male White-Russian rabbits weighing 2.1-2.6 kg were fed either a standard or a high-cholesterol (200 mg/kg) diet, with thyroid function-inhibiting thiouracil (20 mg/kg) combined with cholic acid (40 mg/kg) administered daily in sunflower oil for 3 months. During the last month of the study, estrogens were administered by gavage at a dose of 0.02 or 0.1 mg/kg. RESULTS AND CONCLUSIONS: All three estrogens exerted remarkable antiatherosclerotic effects. Decreases in serum and aortic-wall lipid parameters and the index of atherogenicity were dependent on estrogen dose. Morphological evaluation of the aortic wall (height of plaques, size of plaque relative to aortic half-circumference) showed only weak therapeutic effects with all three estrogens. It is an open question whether the treatment period was too short to reverse the above changes. On the other hand, the data clearly suggest that 17 alpha-estradiol and J811 offer new perspectives for the prevention of atherosclerosis in men, which is similar to that found with 17 beta-estradiol in women.


Subject(s)
Anticholesteremic Agents/pharmacology , Arteriosclerosis/prevention & control , Disease Models, Animal , Estradiol/analogs & derivatives , Estradiol/pharmacology , Free Radical Scavengers/therapeutic use , Hypercholesterolemia/prevention & control , Animals , Anticholesteremic Agents/chemistry , Antithyroid Agents , Arteriosclerosis/blood , Arteriosclerosis/etiology , Arteriosclerosis/pathology , Cholesterol, HDL/blood , Diet, Atherogenic , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , Estradiol/chemistry , Hypercholesterolemia/blood , Hypercholesterolemia/etiology , Hypercholesterolemia/pathology , Male , Rabbits , Random Allocation , Sex Characteristics , Thiouracil
9.
Exp Toxicol Pathol ; 49(1-2): 141-6, 1997 Feb.
Article in English | MEDLINE | ID: mdl-9085089

ABSTRACT

Several studies provided evidence that various prostaglandins exhibited a hepatoprotective effect in vivo as well in vitro the mechanism of which is still in debate. Therefore, the aim of our studies was to examine the effect of PGE2 on some biochemical and morphological alterations in chemically induced liver cirrhosis in rats. A micronodular liver cirrhosis was induced by treatment of rats with thioacetamide for 3 months. Morphologically, the administration of PGE2 for 8 days reduced the extent of vacuolar transformation of the hepatocytes and the density of the nuclear structure without affecting the fibrotic state as assessed by the hepatic hydroxyproline content. The widening of the sinusoids indicated an improved hepatic microcirculation. Administration of PGE2 significantly elevated the percentage portion of arachidonic (20:4) and docosapentaenoic (22:5) acid in the hepatic phospholipids and reduced the ratio 20:3/20:4 fatty acids in comparison to the untreated cirrhotic animals. The hepatic MDA concentration was decreased by 40% in PGE2-treated animals. PGE2 treatment also reduced the content of polar as well as of non-polar carbonyls when compared with the controls. Moreover, treatment with PGE2 lowered iron-induced or iron plus ascorbate-induced MDA production of isolated hepatocytes. From the data it was concluded that the hepatoprotective effect of PGE2 may be related to its antioxidative capacity.


Subject(s)
Antioxidants/pharmacology , Dinoprostone/pharmacology , Liver Cirrhosis, Experimental/prevention & control , 3,4-Methylenedioxyamphetamine/metabolism , Animals , Carcinogens , Cells, Cultured , Fatty Acids/metabolism , Female , Hydroxyproline/metabolism , Lipid Peroxidation/drug effects , Liver/drug effects , Liver/metabolism , Liver/pathology , Liver Cirrhosis, Experimental/chemically induced , Liver Cirrhosis, Experimental/metabolism , Liver Cirrhosis, Experimental/pathology , Phospholipids/metabolism , Rats , Thioacetamide
10.
Cell Biochem Funct ; 14(2): 131-7, 1996 Jun.
Article in English | MEDLINE | ID: mdl-8640953

ABSTRACT

Polyenoylphosphatidylcholine (PPC: 100 or 300 mg kg-1 b.w., by gastric intubation for 30 days) produced a clearcut protection of the liver of rats treated with alloxan (150 mg kg-1 b.w., i.p.). The liver of rats treated with alloxan was characterized by hydropic dystrophy and lymphocytic infiltrations. Treatment with alloxan increased serum gamma-GT and ALAT activities. The liver structure of rats treated with PPC did not differ from the liver of control animals. PPC normalized the biochemical abnormalities caused by the diabetes. The number of pancreatic islets and beta/alpha cell ratio decreased in the diabetic rats. A number of beta-cells in this group did not contain granules. PPC prevented the decrease in the number of islets and the beta/alpha cell ratio in the pancreas of the diabetic rats. The intensity of staining of beta-cell granules in the pancreas of PPC-treated rats had a position intermediate between the control and diabetic groups. Alloxan increased the blood glucose content where treatment with PPC decreased this. The results suggest that PPC acts as a cytoprotector in the liver and pancreas of rats with experimental diabetes induced by alloxan.


Subject(s)
Diabetes Mellitus, Experimental/physiopathology , Liver/drug effects , Pancreas/drug effects , Phosphatidylcholines/pharmacology , Alloxan/adverse effects , Animals , Blood Glucose/analysis , Diabetes Mellitus, Experimental/chemically induced , Fat Emulsions, Intravenous , Lipids/blood , Liver/enzymology , Liver/pathology , Male , Pancreas/pathology , Rats , Rats, Inbred Strains , Transferases/blood
11.
Arch Toxicol ; 65(3): 199-203, 1991.
Article in English | MEDLINE | ID: mdl-2053847

ABSTRACT

Microsomes and isolated hepatocytes from thioacetamide (TAA)-induced macronodularly cirrhotic rat livers were analysed for their susceptibility to unstimulated and stimulated lipid peroxidation measured as malondialdehyde (MDA) formation. In microsomes from TAA-induced macronodularly cirrhotic livers the MDA production stimulated either by ascorbate-iron or by ADP-iron in a NADPH-regenerating system was decreased. Hepatic microsomes from TAA-treated rats exhibited a reduced cytochrome P450 content and lowered activities of ethylmorphine N-demethylase, ethoxycoumarin O-deethylase and epoxide hydrolase. Besides this, the microsomal fatty acid pattern of phosphatidylcholine and phosphatidylethanolamine was significantly changed after 6 months of TAA administration. The 18:2/20:4 ratio of phospholipid fatty acids was markedly increased. In contrast to the microsomes, in isolated hepatocytes from macronodularly cirrhotic livers the iron- and ascorbate-iron-stimulated MDA formation was increased. The hepatocellular GSH content was unaffected by TAA pretreatment, whereas the GSSG content exhibited a significant increase, thus leading to a pronounced reduction of the GSH/GSSG ratio. The calcium channel blocker verapamil (200 microM), known to be able to scavenge OH' radicals produced by the Fenton reaction, revealed an inhibitory effect on ascorbate-iron- and ADP-iron-stimulated lipid peroxidation in hepatocytes from normal as well as TAA-treated livers which is attributed to its antioxidative properties. In summary, lipid peroxidation is altered in TAA-induced macronodularly cirrhotic rat livers. Furthermore, the data clearly show that isolated microsomes and parenchymal cells prepared from cirrhotic livers react differently to prooxidant stimuli.


Subject(s)
Lipid Peroxidation , Liver Cirrhosis, Experimental/metabolism , Thioacetamide/toxicity , Animals , Cytochrome P-450 Enzyme System/analysis , Fatty Acids/metabolism , Female , Liver/metabolism , Liver Cirrhosis, Experimental/chemically induced , Phospholipids/metabolism , Rats , Rats, Inbred Strains
SELECTION OF CITATIONS
SEARCH DETAIL
...